'Cut down to quit' with nicotine replacement therapies in smoking cessation: A systematic review of effectiveness and economic analysis

Health Technology Assessment

Volumn 12, Issue 2, 2008, Pages

  Wang, D ^a   Connock, M ^a   Barton, P ^a   Fry Smith, A ^a   Aveyard, P ^a   Moore, D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DRUGS USED IN THE TREATMENT OF ADDICTION; MENTHOL; NICOTINE; NICOTINE GUM; NICOTINE INHALATOR; NICOTINE PATCH; PLACEBO; UNCLASSIFIED DRUG; NICOTINIC AGENT;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG FORMULATION; DRUG OVERDOSE; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA; GASTROINTESTINAL TOXICITY; GROUP THERAPY; HEADACHE; HEALTH HAZARD; HEART PALPITATION; HICCUP; HUMAN; HYPERTENSION; INFECTION; META ANALYSIS; MOUTH DISCOMFORT; NAUSEA; NAUSEA AND VOMITING; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PASSIVE SMOKING; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHARYNGITIS; PREVALENCE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; SMOKING CESSATION PROGRAM; STATISTICAL SIGNIFICANCE; STOMATITIS; SYSTEMATIC REVIEW; TACHYCARDIA; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WITHDRAWAL SYNDROME; ADULT; AGE; AGED; COST; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SMOKING;

ADULT; AGE FACTORS; AGED; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; SMOKING; SMOKING CESSATION;

EID: 38849171037     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12020     Document Type: Review

References (63)

1. Office for National Statistics. Smoking-related behaviour and attitudes. London: Office for National Statistics. URL: http://www.statistics.gov.uk/downloads/theme_health/Smoking2005.pdf. 2005.
2. Fagerström KO. Can reduced smoking be a way for smokers not interested in quitting to actually quit? Respiration 2005; 72:216-20.
3. Medicines and Healthcare products Regulatory Agency, Committee on Safety of Medicines. Report of the committee on safety of medicines working group on nicotine replacement therapy. URL: http://www.mhra.gov.uk/ home/idcplg?IdcService=GET_FILE&dDocName= CON2023239&RevisionSelectionMethod=LatestReleased. 2006. Accessed January 2007.
4. Cut Down with Nicorette (nicotine) then Stop Backgrounder. URL: http://www.ash.org.uk/html/cessation/Smoking%20reduction/ Pfizer%20%20%20Cut%20down%20with%20Nicorette%20Backgrounder%202005 pdf?cmd=Retrieve&db=PubMed&list_uids=11809253&dopt= Citation. 2005. Accessed May 2006.
5. Thompson GH, Hunter DA. Nicotine replacement therapy. Ann Pharmacother 1998;32:1067-75.
6. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002; 6(16).
7. Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993;18:19-34.
8. True WR, Xian H, Scherrer JF, Madden PA, Bucholz KK, Heath AC, et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch Gen Psychiatry 1999;56:655-61.
9. Fust G, Arason GJ, Kramer J, Szalai C, Duba J, Yang Y, et al. Genetic basis of tobacco smoking: strong association of a specific major histocompatibility complex haplotype on chromosome 6 with smoking behavior, Inter Immunol 2004;16:1507-14.
10. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004;6:583-97.
11. Jefferis BJMH, Power C, Graham H, Manor O. Changing social gradients in cigarette smoking and cessation over two decades of adult follow-up in a British birth cohort. J Public Health 2004;26:13-18.
12. Power C, Graham H, Due P, Hallqvist J, Joung I, Kuh D, et al. The contribution of childhood and adult socioeconomic position to adult obesity and smoking behaviour: an international comparison. Int J Epidemiol 2005;34:335-44.
13. Conrad KM, Flay BR, Hill D. Why children start smoking cigarettes: predictors of onset. Br J Addict 1992;87:1711-24.
14. Tyas SL, Pederson LL. Psychosocial factors related to adolescent smoking: a critical review of the literature. Tob Control 1998; 7:409-20.
15. Engels RC, Knibbe RA, Drop MJ, de Haan YT. Homogeneity of cigarette smoking within peer groups: influence or selection? Health Educ Behav 1997;24:801-11.
16. Ennett ST, Bauman KE. The contribution of influence and selection to adolescent peer group homogeneity: the case of adolescent cigarette smoking. J Pers Soc Psychol 1994;67:653-63.
17. Wang MQ, Eddy JM, Fitzhugh EC. Smoking acquisition: peer influence and self-selection. Psychol Rep 2000;86 (3 Pt 2):1241-6.
18. Wills TA, Cleary SD. Peer and adolescent substance use among 6th-9th graders: latent growth analyses of influence versus selection mechanisms. Health Psychol 1999;18:453-63.
19. West P, Michell L. Smoking and peer influence. In Gorezney AJ, Hersen M, editors. Handbook of pediatric and adolescent health psychology. Boston, MA: Allyn and Bacon; 1999. pp. 179-202.
20. West R, McEwen A, Bolling K, Owen L. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. Addiction 2001;96: 891-902.
21. Lawrence T, Aveyard P, Cheng KK, Griffin C, Johnson G, Croghan E. Does stage-based smoking cessation advice in pregnancy result, in long-term quitters? 18-month postpartum follow-up of a randomized-controlled trial. Addiction 2005; 100:107-16.
22. Office for National Statistics. General household survey 2005: smoking and drinking among adults. URL: http://www.statistics.gov.uk/ StatBase/Product.asp?vlnk=5756. 2006. Accessed Dec 2006.
23. Judge K, Bauld L, Chesterman J, Ferguson J. The English smoking treatment services: short-term. outcomes. Addiction 2005; 100 Suppl 2:46-58.
24. Department of Health. Statistics on smoking cessation services in Health Authorities: England April 2000 to March 2001. URL: http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/ PressReleasesNotices/fs/en?CONTENT_ID=4010832&chk=hbooev. 2001. Accessed December 2006.
25. The Stationery Office. Smoking kills - a White Paper on tobacco. URL: http://www.archive.official-documents.co.uk/document/cm41/4177/ chap01.htm. 1999.
26. Ash London. Nicotine assisted reduction to stop (NARS), guidance for health professionals on this new indication for nicotine replacement therapy. URL: http://www.ash.org.uk/html/cessation/ Smoking%20reduction/NARS051014. pdf. 2005. Accessed December 2006.
27. Gilbert JR, Wilson DM, Singer J, Lindsay EA, Willms DG, Best JA, et al. A family physician smoking cessation program: an evaluation of the role of follow-up visits. Am J Prev Med 1992;8:91-5.
28. Department of Health. The NHS Cancer Plan. London: TSO. URL: http://www.dh.gov.uk/assetRoot/04/01/45/13/0401451.pdf. 2000. Accessed December 2006.
29. Department of Health. Spending review 2004 Public Service Agreement. London: TSO. URL: http://www.dh.gov.uk/assetRoot/04/08/ 69/19/04086919.pdf 2004. Accessed December 2006.
30. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
31. Callum C. The UK smoking epidemic: deaths in 1995. London: Health Education Authority; 1998.
32. McNeill A, Raw M, Whybrow J, Bailey P. A national strategy for smoking cessation treatment in England. Addiction 2005; 100 Suppl 2:1-11.
33. Raw M, McNeill A, Coleman T. Lessons from the English smoking treatment services. Addiction 2005;100 Suppl 2:84-91.
34. Anonymous. IPSOS Omnibus survey amongst 2860 people, UK. Pfizer Ltd, on file. 2004.
35. Centre for Reviews and Dissemination. CRD's guidance for those carrying out or commissioning reviews. Undertaking systematic reviews of research on effectiveness. CRD Report 4. 2nd edition. London: CRD; 2001.
36. Study 98-NNIN-027 (Rennard). A double blind, randomized, placebo-controlled multicenter trial of a nicotine inhaler in smoking reduction. Pfizer Ltd, on file 2001. 397 pp.
37. Study 980-CHC-9021-0013 (Haustein). A double-blind, randomized, placebo-controlled multicenter trial of a nicotine chewing gum in smoking reduction. Pfizer Ltd, on file 2001. 145 pp.
38. Study 98-NNCG-017 (Wood-Baker). A double blind, randomized, placebo-controlled trial of nicotine gum in smoking reduction. A four-month trial. Pfizer Ltd, on file. 2001. 309 pp.
39. Bolliger CT, Zellweger JP, Danielsson T, van Biljon, X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000;321:329-33.
40. Study 96-NNIN-016 (Bolliger). The efficacy and safety of a nicotine oral inhaler in smoking reduction. A double-blind, randomized, comparative clinical study. Pfizer Ltd, on file. 1999. 137 pp.
41. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003;98:1395-402.
42. Study 98-NNCG-014 (Wennike). A double blind, randomized, placebo-controlled trial of nicotine gum in smoking reduction. A four-month trial. Pfizer Ltd, on file. 2001. 389 pp.
43. Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharm Ther 2005; 78:689-96.
44. Study 980-CHC-1013-028 (Batra). A double-blind, randomized, placebo-controlled trial with nicotine 4 mg gum in smoking reduction. A four-month trial. Pfizer Ltd, on file. 2003. 1-302 pp.
45. Etter JF, Laszlo E, Perneger TV. Postintervention effect of nicotine replacement therapy on smoking reduction in smokers who are unwilling to quit: Randomized trial. J Clin Psychopharmacol 2004; 24:174-9.
46. Etter J-F, Laszlo E, Zellweger J-P, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. J Clin Psychopharmacol 2002; 22:487-95.
47. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11(9).
48. Drummond MFJTO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
49. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519.
50. Stapleton J, Stapleton J. Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res 1998;7:187-203.
51. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006; 15:280-85.
52. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;12:21-27.
53. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health 1999;89:1701-7.
54. Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002; 97: 505-16.
55. Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellina SM, Otte P. OTC nicotine patch: effectiveness alone and with brief physician intervention. Am J Health Behav 1999;23:61-69.
56. Koberly H, Epstein M, Maguire MK. Over the counter efficacy of a 15 mg/ 16 hour nicotine patch for smoking cessation: a randomised multi-centre trial. Presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, Match 1999.
57. Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. The safety and effectiveness of the nicotine inhaler for smoking cessation in an over-the-counter setting, Presented at the 9th Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, February 2003.
58. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99:29-38.
59. Netten A, Curtis L. Unit costs of health and social care. Canterbury: Personal and Social Service Research Unit, University of Kent; 2004.
60. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999;354:210-15.
61. National Statistics. Trends in life expectancy by social class 1972-2001. URL: http://www.statistics.gov.uk/downloads/ theme∝pulation/Life_Expect_Social_class_1972_01/ Life_Expect_Social_Class_1972-2001.pdf. 2006; Accessed October 2006.
62. Kind P, Harrdman G, Macran S. UK population norms for EQ-5D. Discussion Paper 172. York: University of York; 1999.
63. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996;275:1247-51.